HIPAA Violations Genetic Counselors Should Know—and How to Avoid Them

HIPAA Privacy Rule and Genetic Information

Under the HIPAA Privacy Rule, genetic information is Protected Health Information (PHI) when it can identify an individual. That includes genetic test orders and results, variant classifications, pedigree charts, risk estimates, notes from counseling sessions, and any family history recorded in a medical record.

Remember that the Genetic Information Nondiscrimination Act (GINA) protects individuals against genetic discrimination in health insurance and employment, but it does not replace HIPAA’s privacy protections. You must still handle identifiable genetic data as PHI, even when GINA applies.

De-identification reduces risk, but re-identification is still possible in small families, rare disease cohorts, or when unusual variants are involved. Treat “de-identified” genetic summaries cautiously and avoid including dates or other indirect identifiers that can point back to the patient or relatives.

Permitted Uses and Disclosures

HIPAA allows use and disclosure of PHI for treatment, payment, and healthcare operations (TPO). You can share genetic information with other treating providers for care coordination, submit records for billing, and use limited data for quality improvement. For non-TPO purposes, you typically need a valid HIPAA Authorization.

HIPAA Authorization

When a disclosure is not otherwise permitted—such as sharing results for marketing, certain research activities without a waiver, or releasing records to non-involved third parties—you must obtain written HIPAA Authorization that specifies what will be shared, with whom, for what purpose, and when the authorization expires. Patients may revoke authorization in writing.

Familial Risk Notification

HIPAA prioritizes the patient’s control over their PHI. The safest path is patient-mediated disclosure: equip the patient with a family letter or portal message they can share with relatives. You may disclose limited information to family or friends involved in the patient’s care if the patient agrees or you infer agreement using professional judgment. Disclosing to relatives without the patient’s permission is generally not allowed unless an exception applies (for example, to prevent or lessen a serious and imminent threat to health or safety). When in doubt, seek authorization or disclose only de-identified risk information.

Research and Public Health

Research uses may proceed with patient authorization, an Institutional Review Board/Privacy Board waiver, or a limited data set under a data use agreement. Certain public health reporting is permitted by law. Always document the legal basis for each disclosure.

Minimum Necessary Standard

For uses and disclosures other than treatment, you must limit PHI to the minimum necessary to accomplish the purpose. Share only the data elements required—such as a variant classification and relevant gene/exon—rather than an entire exome report when a summary suffices.

The minimum necessary standard does not apply to disclosures for treatment between providers; however, applying the principle voluntarily still reduces risk. Implement Role-based Access Controls so users only see the genetic modules and reports they need to perform their jobs.

• Tailor release-of-information to exclude unrelated historical reports, raw data files (e.g., FASTQ/VCF), or sensitive notes not requested.
• Use templated summaries for referrals, including only pertinent findings, interpretation, and next steps.
• Redact identifiers of relatives unless necessary for care and expressly permitted.

Common HIPAA Violations in Genetic Counseling

• Contacting relatives directly about a patient’s results without authorization, outside a recognized exception for serious and imminent threats.
• Over-disclosure during Familial Risk Notification—e.g., naming the proband or including DOB/MRN in family letters.
• Sending entire genomic reports to non-treating parties (schools, employers, or insurers) without a HIPAA Authorization.
• Using unsecured email, texting, or personal cloud storage for genetic reports or raw data.
• Accessing a celebrity, colleague, or family member’s chart without a job-related need (“snooping”).
• Sharing PHI with vendors (transcription, telehealth, app developers) that lack a Business Associate Agreement.
• Failing to contain and investigate a misdirected result or portal release, then neglecting obligations under the Breach Notification Rule.

Best Practices to Avoid Violations

• Standardize consent and documentation: include clear language for sharing with relatives, research options, and when a HIPAA Authorization is required.
• Adopt a patient-first Familial Risk Notification workflow: provide de-identified family letters, portal messages, or referral templates patients can share.
• Practice data minimization: disclose summaries instead of full reports when appropriate; remove nonessential identifiers and raw data attachments.
• Secure communications: use encrypted messaging and patient portals; verify recipient identity; confirm addresses before sending results.
• Train and limit access: implement Role-based Access Controls, “break-the-glass” for exceptional access, and annual privacy training for all staff.
• Monitor and respond: enable Audit Controls, review access logs, and escalate incidents promptly. Follow the Breach Notification Rule for assessment and required notifications.
• Clarify research pathways: coordinate with the IRB, track authorizations and waivers, and separate clinical from research data flows.

Business Associate Agreements

Vendors that create, receive, maintain, or transmit PHI on your behalf are Business Associates. Before sharing PHI, execute a Business Associate Agreement (BAA) that defines permitted uses, security safeguards, subcontractor obligations, breach reporting, and PHI return or destruction at termination.

• Common Business Associates: cloud storage, telehealth platforms, transcription services, secure messaging vendors, data analytics tools, and IT support providers.
• Covered entities acting in their own role (e.g., most clinical laboratories) typically do not need a BAA with you for treatment disclosures, but verify the relationship and data flows.
• Ensure BAAs specify encryption standards, incident timelines, and the right to request evidence of safeguards.

Electronic Health Records Security

• Apply Role-based Access Controls so only authorized users can open genetic modules, reports, and raw data.
• Enable Audit Controls to log who accessed genetic results, when, and what actions were taken; review logs regularly.
• Segment sensitive content (e.g., reproductive counseling notes or raw genomic files) and use “break-the-glass” workflows for rare, justified access.
• Enforce strong authentication, automatic logoff, device encryption, and mobile device management for any endpoint that may store PHI.
• Harden patient portals: default to summaries when appropriate, verify identity for proxy access, and educate patients on sharing responsibly.
• Maintain patching, backups, and disaster recovery procedures that account for large genomic datasets and attachments.

Conclusion

Most HIPAA violations in genetic counseling stem from over-sharing, insecure workflows, or unclear roles with vendors. Center your practice on the minimum necessary standard, patient-mediated family disclosures, and robust technical safeguards. With clear authorizations, strong BAAs, and vigilant auditing, you can protect PHI, honor GINA’s intent, and reduce breach risk.

FAQs.

What constitutes a HIPAA violation in genetic counseling?

A violation occurs when identifiable genetic information is used or disclosed in a way not permitted by HIPAA—such as contacting relatives without a lawful basis, sending full genomic reports to non-treating parties without HIPAA Authorization, storing PHI insecurely, snooping in charts, or failing to follow the Breach Notification Rule after an incident.

How can genetic counselors protect genetic information under HIPAA?

Use patient portals and encrypted messaging, limit disclosures to the minimum necessary, enable Role-based Access Controls and Audit Controls, standardize patient-mediated Familial Risk Notification, and execute strong Business Associate Agreements with any vendor handling PHI.

What are the consequences of failing to comply with HIPAA in genetic counseling?

Consequences can include corrective action plans, civil monetary penalties, reputational harm, patient complaints, loss of contracts, and—in cases of willful neglect—more severe penalties. Breaches also trigger notification duties to affected individuals and regulators.

When is patient authorization required for genetic information disclosure?

You need HIPAA Authorization when a disclosure is not otherwise permitted by HIPAA—such as for marketing, many research uses without a waiver, or releases to non-involved third parties. For treatment, payment, and healthcare operations, authorization is generally not required, but you should still limit information to what is necessary.